This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2000 Mar;15(3):734-5.

doi: 10.1093/humrep/15.3.734.

The clinical benefits of recombinant gonadotrophins

PMID: 10686229
DOI: 10.1093/humrep/15.3.734

Comment

The clinical benefits of recombinant gonadotrophins

E R Hernandez. Hum Reprod. 2000 Mar.

. 2000 Mar;15(3):734-5.

doi: 10.1093/humrep/15.3.734.

Author

PMID: 10686229
DOI: 10.1093/humrep/15.3.734

No abstract available

PubMed Disclaimer

Comment on

Effects of recombinant human follicle stimulating hormone on cultured human granulosa cells: comparison with urinary gonadotrophins and actions in preovulatory follicles.
Mason HD, Mannaerts B, de Leeuw R, Willis DS, Franks S. Mason HD, et al. Hum Reprod. 1993 Nov;8(11):1823-7. doi: 10.1093/oxfordjournals.humrep.a137941. Hum Reprod. 1993. PMID: 8288744
What are the clinical benefits of recombinant gonadotrophins?: the development of recombinant FSH (Puregon((R))): a scientific business.
Out HJ, Bennink HJ, de Laat WN. Out HJ, et al. Hum Reprod. 1999 Sep;14(9):2189-90. doi: 10.1093/humrep/14.9.2189. Hum Reprod. 1999. PMID: 10469679 Review. No abstract available.
A prospective, randomized clinical trial comparing 150 IU recombinant follicle stimulating hormone (Puregon((R))) and 225 IU highly purified urinary follicle stimulating hormone (Metrodin-HP((R))) in a fixed-dose regimen in women undergoing ovarian stimulation.
Hoomans EH, Andersen AN, Loft A, Leerentveld RA, van Kamp AA, Zech H. Hoomans EH, et al. Hum Reprod. 1999 Oct;14(10):2442-7. doi: 10.1093/humrep/14.10.2442. Hum Reprod. 1999. PMID: 10527965 Clinical Trial.

Similar articles

Outcome from consecutive in-vitro fertilization/intracytoplasmic sperm injection attempts in the final group treated with urinary gonadotrophins and the first group treated with recombinant follicle stimulating hormone.
Jacob S, Drudy L, Conroy R, Harrison RF. Jacob S, et al. Hum Reprod. 1998 Jul;13(7):1783-7. doi: 10.1093/humrep/13.7.1783. Hum Reprod. 1998. PMID: 9740423
Cost-effectiveness of recombinant versus urinary follicle stimulating hormone; whose point of view?
Ola B, Afnan M, Sharif K, Hammadieh N, Papaioannou S, Coomarasamy A. Ola B, et al. Acta Obstet Gynecol Scand. 2001 Dec;80(12):1141-2. doi: 10.1034/j.1600-0412.2001.801213.x. Acta Obstet Gynecol Scand. 2001. PMID: 11846714 No abstract available.
What are the clinical benefits of recombinant gonadotrophins? Clinical efficacy of recombinant gonadotrophins.
Balen AH, Hayden CJ, Rutherford AJ. Balen AH, et al. Hum Reprod. 1999 Jun;14(6):1411-7. doi: 10.1093/humrep/14.6.1411. Hum Reprod. 1999. PMID: 10357948 Review. No abstract available.
Issues of bioequivalence and cost equivalence.
Mahutte NG, Arici A, Duleba A. Mahutte NG, et al. Fertil Steril. 2002 Aug;78(2):439-40; author reply 440. doi: 10.1016/s0015-0282(02)03261-2. Fertil Steril. 2002. PMID: 12137897 No abstract available.
Bye-bye urinary gonadotrophins? Recombinant FSH: a real progress in ovulation induction and IVF?
Gleicher N, Vietzke M, Vidali A. Gleicher N, et al. Hum Reprod. 2003 Mar;18(3):476-82. doi: 10.1093/humrep/deg099. Hum Reprod. 2003. PMID: 12615810 Review.

See all similar articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems